Induced activation in dendritic cells
AssigneeBaylor College of Medicine
InventorsDavid Spencer, Brent Hanks, Kevin Slawin
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
Claims16
An ex vivo nucleic acid comprising a polynucleotide promoter sequence operatively linked to a polynucleotide sequence encoding a chimeric protein comprising
- (a) a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain, and
- (b) a ligand binding region comprising a FKBP12(V36) polypeptide.
An ex vivo nucleic acid comprising a polynucleotide promoter sequence operatively linked to a polynucleotide sequence encoding a chimeric protein comprising
- (a) a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain, and
- (b) an FK506 ligand binding polypeptide region that binds to AP1903 or AP20187.
Dependencies are inferred from the claim text.